Strategic Clinics ARENSIA operates phase IB to PROOF OF CONCEPT trials with dedicated clinics located within or near major university and private hospitals across Europe and the US, enabling targeted access to niche patient populations and potential partnerships with academic medical centers.

Time and Cost Advantage The unique site concentration and streamlined operations reportedly reduce trial timelines by about 60 percent and cut typical Phase IB/IIA PROOF OF CONCEPT budgets by around 50 percent, offering a compelling value proposition to sponsors seeking faster, cheaper early‑phase data.

Strong Repeat Business A high 93 percent repeat business rate signals strong sponsor trust, consistent performance, and potential for multi‑study collaborations or extended programs with current clients and referral opportunities within the biotech and pharma ecosystem.

Strategic Partnerships Recent and ongoing partnerships with universities and oncology institutes in Romania, Moldova, Georgia, Ukraine, Bulgaria, and the US indicate growing regional access and potential cross‑border collaboration opportunities for expanded trial sites and academic co‑development projects.

Growth and Visibility Active expansion in Eastern Europe and collaborations with notable biotech players (for example Pasithea Therapeutics) suggest momentum and a ripe market for CRO‑like services; leverage partner networks and case studies to approach additional sponsors seeking efficient early‑phase execution.